RxDoctor Payments Data

Laura Snyder, MD

Neurological Surgery · Phoenix, AZNPI 1366606212

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Globus Medical at 43.4% of the total. Reporting peaked in 2023 at $77,940 and has fallen 77.9% since, to $17,196 in 2025.

$191,339in general payments, 2019–2025

Across 149 payments — averaging $1284.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$83K
  • Aesculap Implant Systems, LLC$58K
  • Medtronic$40K
  • Alphatec Spine, Inc$6K
  • Medical Device Business Services, Inc.$3K
  • Impactortho, Inc.$617
  • plus $452 from 8 others
$36,976in research payments, 2019–2025

Across 4 payments — averaging $9244.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$37K

What the payments were for

  • Consulting fees$98,55952%
  • Speaking & faculty fees$67,06935%
  • Travel & lodging$23,28612%
  • Food & beverage$2,4261%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$191,339 in reported general payments places this provider in the 85th percentile of 173 neurological surgery providers in Arizona.

See all neurological surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$246,913
Medicare patients
247
Services billed
693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin43$379
Meloxicam12$56

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →